MREO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MR

Mkt Cap

$49.0M

Volume

712.77K

Next Earnings

November 9th

Loading chart

MR

MREOMereo BioPharma Group plc American Depositary Shares

MREO

Pay with—

Available Balance0.00

MR

Mkt Cap

$48.4M

Volume

712.77K

Next Earnings

November 9th

Chart Earnings News About Insider Filings

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNORosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Soleno Therapeutics, where investors who purchased stock between March 26, 2025 and November 4, 2025 may be entitled to compensation. The lawsuit alleges Soleno made false statements about safety concerns related to its DCCR drug candidate, including fluid retention issues in clinical trials, which posed greater risks than disclosed and reduced commercial viability. The lead plaintiff deadline is May 5, 2026.GlobeNewswire Inc. · Apr 3, 2026

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.GlobeNewswire Inc. · Apr 3, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREOPomerantz LLP has filed a class action lawsuit against Mereo BioPharma Group plc alleging securities fraud. The lawsuit stems from Mereo's announcement on December 29, 2025, that its Phase 3 Orbit and Cosmic studies failed to meet primary endpoints, causing the stock to plummet 87.7% to $0.29 per share. Investors have until April 6, 2026, to request Lead Plaintiff status.GlobeNewswire Inc. · Mar 31, 2026

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.GlobeNewswire Inc. · Mar 27, 2026

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. Investors who purchased Mereo securities between June 5, 2023 and December 26, 2025 are encouraged to join the case, with a lead plaintiff deadline of April 6, 2026.GlobeNewswire Inc. · Mar 24, 2026

Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)Law firm Holzer & Holzer, LLC announced April 6, 2026 lead plaintiff deadlines for shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc., alleging materially false statements and/or failure to disclose material facts. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.GlobeNewswire Inc. · Mar 24, 2026

MREO DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREORosen Law Firm reminds investors in Mereo BioPharma Group plc (NASDAQ: MREO) of the April 6, 2026 lead plaintiff deadline for a securities class action. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's efficacy while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.GlobeNewswire Inc. · Mar 22, 2026

Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Mereo BioPharma Group plc alleging that the company made materially false and misleading statements to investors regarding its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their primary endpoints. The lawsuit covers investors who purchased Mereo securities between June 5, 2023 and December 26, 2025, with a lead plaintiff deadline of April 6, 2026.GlobeNewswire Inc. · Mar 17, 2026

Holzer & Holzer, LLC Reminds Investors of April 6, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BlackRock TCP Capital Corp. (TCPC), Mereo BioPharma Group plc (MREO), POMDOCTOR LIMITED (POM), and Ultragenyx Pharmaceutical Inc. (RARE)Law firm Holzer & Holzer reminds investors of April 6, 2026 deadlines to seek lead plaintiff status in shareholder class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc. The lawsuits allege materially false statements and/or failure to disclose material facts regarding investment valuations, clinical trial results, and fraudulent stock promotion schemes.GlobeNewswire Inc. · Mar 14, 2026

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREORosen Law Firm is encouraging investors who purchased shares of Mereo BioPharma Group plc (MREO) between June 5, 2023 and December 26, 2025 to join a securities class action lawsuit. The lawsuit alleges that Mereo provided misleading statements about Phase 3 clinical trials for setrusumab, expressing confidence in the drug's success while concealing that the trials failed to meet their primary endpoints, causing investors to purchase shares at artificially inflated prices.GlobeNewswire Inc. · Mar 13, 2026

to start trading

MR

MREOMereo BioPharma Group plc American Depositary Shares

MREO

Pay with—

Available Balance0.00

Your PositionYou don't own any MREO yet.

Related Tickers

Earnings